Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Postherpetic Neuralgia (PHN) Market Revenue Growth Supported By A CAGR Of 1.05% Through 2030
The market for postherpetic neuralgia (PHN) has experienced robust expansion in recent years, rising from $0.77 billion in 2025 to an estimated $0.82 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.8%. This historic growth has been fueled by factors such as a higher occurrence of herpes zoster infections, a scarcity of neuropathic pain therapies, dependence on opioid-based pain relief methods, an expanding demographic of older adults, and a steady increase in the availability of hospital-based pain management programs.
The postherpetic neuralgia (PHN) market is projected to experience robust expansion over the coming years, reaching an estimated $1.06 billion by 2030 with a compound annual growth rate (CAGR) of 6.5%. This anticipated growth during the forecast period is driven by the development of targeted neuropathic pain therapies, a rising uptake of biologic and branded drugs, the expansion of online pharmacy distribution channels, an increasing emphasis on patient-centric pain management, and the growth of outpatient and ambulatory care facilities. Key trends shaping this period include a higher prevalence of shingles among the aging population, a growing shift toward non-opioid pain management approaches, increased utilization of transdermal and topical pain relief products, greater demand for long-term chronic pain solutions, and enhanced awareness coupled with earlier diagnosis of PHN.
Download A Free Sample Report For Comprehensive Market Insights:
Postherpetic Neuralgia (PHN) Market Development Factors: Which Trends Are Supporting Demand?
The growing occurrence of chronic pain conditions is anticipated to fuel the expansion of the postherpetic neuralgia (PHN) market in the near future. Chronic pain is defined as persistent or recurrent pain that lasts for more than three months, often extending beyond the expected healing period of an illness or injury, and it significantly impacts daily activities and overall quality of life. This rise in chronic pain cases is largely linked to an aging population, since older individuals are more susceptible to degenerative conditions such as arthritis and neuropathy, which frequently result in ongoing discomfort. Postherpetic neuralgia serves as a valuable tool in chronic pain research by offering a clear framework for investigating nerve-related pain mechanisms and assessing long-term therapeutic approaches. As an example, a report from the Office for Health Improvement and Disparities, a UK government agency published in January 2024, indicated that around 18.4% of people aged 16 and older reported having a long-term musculoskeletal (MSK) condition in 2023, reflecting an increase from 17.6% in 2022. Consequently, the rising prevalence of chronic pain conditions is accelerating the growth of the postherpetic neuralgia (PHN) market.
Postherpetic Neuralgia (PHN) Market Segment Analysis: What Are The Major Market Categories?
The postherpetic neuralgia (phn) market covered in this report is segmented –
1) By Type: Patches, Drugs, Opioids
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End Users: Hospitals, Clinics, Other End Users
Subsegments:
1) By Patches: Transdermal Drug Delivery Patches, Analgesic Patches
2) By Drugs: Prescription Drugs, Over-The-Counter (OTC) Drugs, Generic Drugs, Branded Drugs, Biologic Drugs
3) By Opioids: Natural Opioids, Semi-Synthetic Opioids, Synthetic Opioids, Opioid Analgesics, Opioid Antagonists
Postherpetic Neuralgia (PHN) Market Transformation Trends: Which Innovations Are Driving Change?
Leading players in the postherpetic neuralgia (PHN) space are prioritizing efforts to secure regulatory clearances, aiming to broaden their product offerings, strengthen their market positions, and address the substantial unmet demand for treatments that are both more effective and better tolerated. Such regulatory approvals are essentially formal authorizations from government health bodies that permit the legal marketing and use of a drug or therapy for a designated condition. As an example, in February 2023, Zydus Lifesciences Ltd., a pharmaceutical firm based in India, obtained final approval from the United States Food and Drug Administration to produce and sell once-daily generic Gabapentin Tablets in 300 mg and 600 mg dosages, prescribed for managing postherpetic neuralgia. These gabapentin tablets are aimed at alleviating PHN, a neuropathic pain condition triggered by nerve injury resulting from the reactivation of the varicella-zoster virus. The recommended dosage regimen for PHN begins with 300 mg on day one, escalates to 600 mg (divided as 300 mg twice daily) on day two, and reaches 900 mg (administered as 300 mg three times daily) on day three, with the possibility of titration up to a maximum of 1800 mg per day (given as 600 mg three times daily) based on pain response.
Postherpetic Neuralgia (PHN) Market Leading Companies Driving Competitive Growth
Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grünenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd.
Access The Complete Postherpetic Neuralgia (PHN) Market Report:
Postherpetic Neuralgia (PHN) Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in the postherpetic neuralgia (phn) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model